Amendment dated June 9, 2008

Reply to Office Action of December 19, 2007

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the

application:

**Listing of Claims:** 

Claim 1 (cancelled).

Claim 2 (currently amended): A cell [for] expressing gamma-aminobutyric acid (GABA)

isolated from a human NT2 cell line[[.]], wherein the cell comprises a cell deposited

with the American Type Culture Collection (ATCC) Manassas, Virginia (USA), under

Designation No. PTA-7154.

Claim 3 (cancelled).

Claim 4 (currently amended): A cell [for] expressing gamma-aminobutyric acid (GABA)

cloned from a cell obtained from a human NT2 cell line.

Amendment dated June 9, 2008

Reply to Office Action of December 19, 2007

Claims 5-8 (cancelled).

Claim 9 (currently amended): A method of treating a neurological disease, condition, or disorder, comprising:

administering to transplanting in a subject in need thereof a suitable amount of at least one member selected from the group consisting of a cell transplant material, gamma-aminobutyric acid (GABA) expressing hNT2 cells cloned from a human NT2 cell line, in or adjacent to the spinal cord of the subject, and a combination thereof.

Claims 10-14 (cancelled).

Claim 15 (currently amended): A composition for treating a neurological disease, condition, or disorder of the central or peripheral nervous system, comprising:

- a) a cell expressing a bioagent <u>comprising</u> selected from the group consisting of serotonin (5HT), and gamma-aminobutyric acid (GABA), the cell having been cloned from a cell obtained from a human NT2 cell line; and
- b) a suitable carrier.

Amendment dated June 9, 2008

Reply to Office Action of December 19, 2007

Claim 16 (original): The composition of Claim 15, wherein:

 the neurological disease, condition, or disorder comprises one or more of pain, spasticity, epilepsy, depression, mobility disorder, sensory disorder,

Parkinson's, or Alzheimer's disease.

Claims 17-27 (cancelled).

Claim 28 (original): The cell of Claim 4, wherein:

the cell comprises a cell deposited with the American Type Culture Collection (ATCC) Manassas, Virginia (USA), under Designation No. PTA-7154.

Claim 29 (cancelled).

Claim 30 (new): A method of treating a neurological disease, condition, or disorder, comprising:

transplanting in a subject in need thereof a suitable amount of gammaaminobutyric acid (GABA) expressing hNT2 cells cloned from a human NT2 cell line, in or adjacent to the brain of the subject.

Amendment dated June 9, 2008

Reply to Office Action of December 19, 2007

Claim 31 (new): A method of treating a neurological disease, condition, or disorder, comprising:

transplanting in a subject in need thereof a suitable amount of gamma-aminobutyric acid (GABA) expressing hNT2 cells cloned from a human NT2 cell line, at a location in or adjacent the central or peripheral nervous system of the subject.